Security Snapshot

POSEIDA THERAPEUTICS INC - Common Stock, par value $0.0001 per share (PSTX) Institutional Ownership

CUSIP: 73730P108

13F Institutional Holders and Ownership History from Q3 2020 to Q4 2025

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Shares outstanding
98,365,673
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • PSTX - POSEIDA THERAPEUTICS INC - Common Stock, par value $0.0001 per share is tracked under CUSIP 73730P108.
  • Latest finished 13F holder period is not available.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
  • SEC-reported value moved from $344,528 to $0.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

73730P108

Latest holder period

n/a

13F holders

13D/G owners

0

CIK / CUSIP context first

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
22
Latest
n/a
Rows shown
1-22 of 22
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$344,528 0
2025 Q3 120,464 $344,528 +$344,528 $2.86 1
2025 Q2 0 $0 -$308,000 0
2025 Q1 100,000 $308,000 -$512,769,976 $3.08 1
2024 Q4 53,970,727 $518,070,752 +$17,008,807 $9.60 114
2024 Q3 53,512,171 $153,042,595 +$889,907 $2.86 94
2024 Q2 52,954,774 $154,591,146 -$128,086 $2.92 90
2024 Q1 52,747,602 $168,247,853 +$23,931,180 $3.19 90
2023 Q4 45,227,069 $151,964,876 +$388,861 $3.36 90
2023 Q3 45,211,925 $107,601,397 +$2,937,881 $2.38 85
2023 Q2 44,463,763 $78,239,697 -$5,736,756 $1.76 91
2023 Q1 44,145,641 $135,966,651 +$3,079,454 $3.08 101
2022 Q4 42,639,196 $225,970,611 +$18,484,174 $5.30 88
2022 Q3 40,082,757 $141,733,596 +$62,472,178 $3.53 66
2022 Q2 22,502,781 $58,056,750 -$5,315,127 $2.58 51
2022 Q1 24,182,970 $108,362,581 -$12,481,973 $4.48 62
2021 Q4 25,853,738 $176,062,275 -$2,997,826 $6.81 59
2021 Q3 26,151,081 $190,704,000 -$17,048,693 $7.29 62
2021 Q2 27,875,232 $279,302,000 -$10,459,200 $10.02 69
2021 Q1 28,928,358 $276,249,644 +$21,624,136 $9.55 62
2020 Q4 26,347,216 $288,434,000 +$15,183,869 $10.97 55
2020 Q3 25,108,950 $217,383,620 +$217,383,620 $8.87 51
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .